Stevanato Group S.p.A. (STVN) Form 6-K — Nov 3, 2026
Stevanato Group reported Q3 2026 revenue of €326M, up 8% year over year, driven by 11% organic growth in its Biopharmaceutical and Diagnostic Solutions segment that offset a 12% decline in Engineering. Adjusted EBITDA rose 14% to €88.8M with margin expanding 150 bps to 27.2%, and the company reiterated its FY26 guidance of €1.260B-€1.280B in revenue and €0.60-€0.62 adjusted EPS. The key caution: Stevanato now expects lower GLP-1 volumes than previously anticipated for fiscal 2027, which will temporarily moderate growth.
Key figures
- Eps
- €0.16 adjusted diluted (€0.15 reported)
- Revenue
- €326M (Q3 2026, +8% yoy)
- Guidance
- FY26 revenue €1.260B-€1.280B (8-10% implied organic growth); adjusted EBITDA €335.0M-€345.2M; adjusted EBITDA margin ~26.8% at midpoint; adjusted DEPS €0.60-€0.62; CAPEX €230M-€240M; expects LSD growth in 2027
- Net Income
- €41.8M reported; €44.0M adjusted
- Total Debt
- €353.7M net debt
- Revenue Yoy
- 8%
- Cash Position
- €114.9M cash and equivalents at Sep 30, 2026
- Gross Proceeds
- 0
- Capex
- €44.8M
- Bds revenue
- €294M (+10% yoy, +11% organic)
- Hvs revenue
- €149M (46% of total)
- Free cash flow
- €21.7M
- Adjusted ebitda
- €88.8M (+14% yoy)
- Glp1 revenue share
- approx. 17-18% of revenue
- Engineering revenue
- €32.0M (-12% yoy)
- Gross profit margin
- 29.1% (-10 bps)
- Operating cash flow
- €57.6M
- Adjusted ebitda margin
- 27.2% (+150 bps)
- Operating profit margin
- 18.5% (+110 bps); adjusted 19.4% (+90 bps)
- Biologics ex glp1 growth
- over 30% yoy
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.